Clinical trials: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Condition Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.
- Trial name
- NCT06338995
- Testing
- LY3650150, Standard therapy for INCS
- Where
- 202 sites in United States, Argentina and 18 more
- Volunteers
- 510 people
- Sponsor
- Eli Lilly and Company
Severe Asthma, Chronic Rhinosinusitis With Nasal Polyps(CRSwNP)
Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
The objectives of this study are to describe the incidence of adverse events and the effectiveness of tezepelumab in patients receiving tezepelumab as indicated for severe asthma or CRSwNP in South Korea.
- Trial name
- Tezepelumab (NCT06998095)
- Volunteers
- 210 people
- Sponsor
- AstraZeneca